CNS Pharmaceuticals, Inc. Files Amendment No. 1 to 2025 Annual Report: Key Details for Investors

HOUSTON, TX – April 30, 2026 – CNS Pharmaceuticals, Inc. (Nasdaq: CNSP), a biopharmaceutical company focused on the development of novel treatments for brain and central nervous system cancers, has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment provides significant disclosures regarding the company’s executive compensation, governance, director and executive stock ownership, and related party transactions.

Key Points from the Amended 10-K/A Filing

• Purpose of Amendment: The amendment was filed to include information required by Items 10 through 14 of Part III of Form 10-K, which were previously omitted with the intention of incorporating them by reference from the company’s definitive proxy statement. As the proxy statement was not filed within 120 days of fiscal year-end, the company included the information directly in this amendment.
• Company Status:
  • Not a well-known seasoned issuer.
  • Non-accelerated filer and smaller reporting company; not an emerging growth company.
  • Not a shell company.
• Shares and Market Value:
  • Aggregate market value of voting equity held by non-affiliates as of June 30, 2025: \$8.78 million.
  • Shares of common stock outstanding as of April 27, 2026: 811,449 shares.
• Stock Ownership:
  • Two institutional shareholders each hold more than 5% of shares:
    • Stonepine Capital Management, LLC: 48,827 shares (6.0%)
    • Ikarian Capital, LLC: 45,830 shares (5.6%)
• Executive Compensation:
  • The company disclosed details of executive and director compensation for 2024 and 2025, including salary, bonus, stock awards, and option awards.
  • Summary Compensation Table and Outstanding Equity Awards tables provided detailed breakdowns of base salary, stock awards, and stock options, including vesting schedules and exercise prices.
  • Notably, some executive officers received significant option and equity grants, with vesting tied to share price performance milestones (ranging from \$6 to \$24 per share).
• Corporate Governance and Policies:
  • The company’s Board has adopted an Insider Trading Policy prohibiting directors, officers, and employees from hedging or offsetting transactions on CNSP shares without prior approval.
  • Standing committees include Audit, Compensation, and Nominating & Corporate Governance Committees, all with adopted charters available on the company’s website.
• Section 16(a) Compliance: All executive officers, directors, and significant shareholders were in compliance with required SEC filings for changes of stock ownership in 2025.
• Related Party Transactions:
  • The Audit Committee is responsible for reviewing and approving all related party transactions in advance, following Regulation S-K Item 404 requirements.
• Equity Compensation Plans:
  • As of April 27, 2026:
    • 19,873 shares subject to outstanding options, warrants, and rights under equity compensation plans.
    • Weighted-average exercise price: \$2,815.21 (Note: May reflect reverse splits or other adjustments).
    • 85,429 shares remain available for future issuance under the 2017 and 2020 stock plans.
• Certification and Compliance:
  • Principal Executive Officer (Rami Levin) and Principal Financial Officer (Steve O’Loughlin) certified the accuracy and completeness of the amended filing.
  • No financial statements were included or amended in this filing; only Part III information was updated.

Potentially Price-Sensitive or Shareholder-Relevant Information

• Equity Holdings and Institutional Ownership:
  • Stonepine Capital and Ikarian Capital collectively control over 11% of the company’s outstanding shares. Any changes in their positions could significantly impact share price and investor sentiment.
• Executive Compensation Structure:
  • Significant portions of executive compensation are performance-based, with option vesting tied to stock price milestones well above current market levels (\$6 to \$24 per share). This indicates alignment with shareholder interests but also sets ambitious targets.
• Low Public Float and Outstanding Shares:
  • With only 811,449 shares outstanding and a low public float, the stock may be subject to higher volatility. Any significant news, change in ownership, or performance milestone achievement could cause outsized moves in share price.
• No Financial Restatements or Corrections:
  • The filing confirms that there have been no corrections or restatements of prior financial statements and no incidents requiring recovery of incentive-based compensation. This provides reassurance regarding the integrity of previous financial disclosures.
• Governance and Compliance:
  • CNS Pharmaceuticals maintains strong compliance with insider trading policies and reporting requirements, which may support investor confidence.

Conclusion

The filing of Amendment No. 1 to the 2025 Annual Report by CNS Pharmaceuticals, Inc. is significant for investors as it provides transparency around governance, compensation, and insider ownership. The company’s low public float, concentrated institutional ownership, and performance-based executive compensation structure could all contribute to share price volatility and investor interest going forward. Stakeholders should monitor for any further changes in executive compensation, board structure, or large shareholder positions, as these could have material impacts on the company’s valuation and stock performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult a registered investment advisor before making any investment decisions. The information above is based on public filings as of April 30, 2026 and may not reflect subsequent events or changes.

View CNS Pharmaceuticals, Inc. Historical chart here